The various grants obtained to date testify to the quality of MUTABILIS research
2017 – ENABLE grant for DABOCIN program
In 2017 Mutabilis DABOCIN program was granted the ENABLE support (http://nd4bb-enable.eu/). ENABLE program belongs to the New Drugs For Bad Bugs (ND4BB) action (http://www.nd4bb.eu/) and supports / accelerates the development of novel antibiotics targeting the most worrisome Gram-negative pathogens. ND4BB is funded by IMI (Innovative Medicine Initiative), the largest Publi-Private Partnership in the field of Life Sciences (http://www.imi.europa.eu/). Through this platform Mutabilis has access to a whole range of services supporting its Dabocins program up to and including the phase 1 clinical trials.
2018 – Grant for ORAL CEPHALOSPORIN/BETA-LACTAMASE INHIBITOR COMBINATION program
To be announced soon.